ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(3.25) per share which missed the analyst consensus estimate of $(1.95) by 66.67 percent. This is a 55.78 percent increase over losses of $(7.35) per share from the same period last year.